Stryker Corporation research snapshot
SYK AI stock analysis currently reads Stryker Corporation as a high-quality medical technology franchise that is rebuilding momentum after the March 2026 cybersecurity incident. At the August 2, 2026 data cutoff, SYK closed at $325.70 on July 31, 2026 with market capitalization near $124.93 billion, verified as $325.70 times 383.57 million shares with 0.00% deviation. The Q2 2026 report, released July 30, 2026, delivered reported net sales of $6.589 billion up 9.4%, organic sales growth of 9.0%, and adjusted EPS of $3.69 up 17.9%, beating the consensus of $3.49, while management narrowed full-year 2026 guidance to organic net sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10. The stock still fell 6.42% on July 31 because the Inari Peripheral Vascular supply disruption caused lost sales, the EPS beat did not flow through to the full-year range, and analysts cut price targets. The SYK AI stock forecast therefore uses scenario ranges, not a certain prediction, and this page is informational research rather than investment advice.
Current price
$325.70 close on July 31, 2026
Market cap
$124.93 billion
AI score
72 / 100
Rating
High-quality MedTech recovering from the March 2026 cyber incident, with strong Q2 2026 organic growth offset by a premium valuation, cyber recovery costs, and new Inari supply friction
Trend status
Mixed: holding above the 50-day and 100-day moving averages but below the 200-day after a sharp post-earnings pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Stryker sells implants, surgical equipment, neurovascular and peripheral vascular products, emergency care tools, endoscopy systems, and robotic-assisted orthopedic platforms to hospitals, surgeons, and healthcare providers. | High |
| Moat | The moat comes from surgeon training, clinical workflow familiarity, Mako robotics with more than 2.5 million procedures across 47 countries, hospital relationships, regulatory know-how, broad product breadth, and scale. | High |
| Management | CEO Kevin A. Lobo has led a long acquisition and innovation cycle. Q2 2026 showed operational recovery with 9.0% organic growth and 17.9% adjusted EPS growth, but execution is now judged on production ramp, Inari recovery, cyber remediation costs, and margin delivery. | Medium-high |
| Financial trend | Q2 2026 net sales rose 9.4% to $6.589 billion with 9.0% organic growth, and adjusted EPS rose 17.9% to $3.69. FY2025 net sales rose 11.16% to $25.116 billion with net earnings of $3.246 billion. | High |
| Valuation | At $325.70, financial_rigor.py calculates about 33.75x TTM EPS, 20.32x forward EPS, 26.57x free cash flow, 4.84x sales, 5.21x book value, and a 1.08% dividend yield. | High |
| Technical trend | SYK closed at $325.70 on July 31, 2026, above the 50-day and 100-day moving averages near $317 and $321 but below the 20-day near $327 and the 200-day near $343, after a 6.42% post-earnings drop. | Medium |
| Risk level | Risk is medium-high because the Inari supply disruption and cyber recovery costs are active, valuation is premium, Medicare reimbursement pressure is rising, and hospital capital cycles and product liability remain live risks. | Medium-high |
| AI confidence | High for historical financials, Q2 2026 results, and market data. Medium for forecast ranges because margins, Inari recovery, procedure volumes, reimbursement, and multiples can re-rate quickly. | High data confidence |
| Investment certainty | Medium certainty. Stryker is a strong business with a credible recovery, but the current price still embeds premium expectations and fresh execution friction, so this page gives a framework rather than a buy or sell instruction. | Medium |
SYK AI stock forecast
The SYK AI stock forecast is scenario-based around the $325.70 closing price. Using the narrowed 2026 adjusted EPS guidance midpoint near $15.03, financial_rigor.py produced three-year values near $549 in a bull case, $398 in a base case, and $239 in a bear case. These are not price promises. They show how sensitive SYK is to adjusted EPS growth, margin recovery, Inari recovery, and the earnings multiple investors assign to a premium MedTech compounder.
$520 to $570
More likely if organic sales stay near or above 9%, the production ramp fully clears backlogs, Inari backorders are resolved by the end of Q3 with no durable share loss, Mako and Mako RPS adoption keeps growing, margins expand toward the 150 basis point three-year target, and investors keep a premium low-to-mid-20s earnings multiple.
$380 to $420
More likely if Stryker delivers the narrowed 8.3% to 9.3% organic growth, adjusted EPS lands near the $14.95 to $15.10 range and then compounds at a high single-digit rate, cyber and Inari costs stay contained, and SYK trades around a low-20s forward multiple.
$220 to $260
More likely if cyber remediation costs run higher than planned, Inari and Peripheral Vascular lose share durably, procedure growth slows or Medicare reimbursement hits hips and knees harder, acquisitions dilute returns, or the market compresses the multiple toward the high-teens area.
SYK AI technical analysis
SYK AI technical analysis is mixed as of the August 2, 2026 data cutoff. The stock closed at $325.70 on July 31, 2026 after a 6.42% drop on the Q2 earnings reaction, ending above the 50-day moving average near $317.19 and the 100-day near $321.29 but below the 20-day near $327.49 and the 200-day near $343.17. The chart should be rechecked with live data before any trade.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $325.70 | July 31, 2026 closing quote used for this static page and market-cap verification, down 6.42% on the earnings reaction. |
| Near support | $317 to $321 | The 50-day moving average near $317.19 and the 100-day near $321.29 form a support cluster that the July 31 intraday low of $317.62 tested and held. |
| Deeper support | $311 to $316 | This band sits below the July 31 low and would be the next area to watch if the moving-average cluster breaks. |
| Support below | $300, then $281 | The $300 area is a psychological level, and the 52-week low near $281.00 is the major downside reference on the daily chart. |
| Near resistance | $327 to $334 | The 20-day moving average near $327.49 and the July 31 intraday high near $334.46 cap the immediate bounce. |
| Next resistance | $343 to $348 | The 200-day moving average near $343.17 and the July 30 close near $348.04 are the next upside hurdles after the gap down. |
| Major resistance | $365 to $402 | Analyst targets cluster from $350 to $420, and the 52-week high near $401.99 marks the top of the one-year range. |
| Moving averages | 20-day $327.49, 50-day $317.19, 100-day $321.29, 200-day $343.17 | Barchart reported these values at the July 31, 2026 close; price sits between the rising short-term supports and the 200-day trend line. |
| Momentum | Neutral | 14-day RSI was near 49.87 on StockAnalysis and Barchart, and 14-day ADX was near 15.69, indicating a range-bound, trend-less condition after the drop. |
| Volume | 4.54 million vs 2.37 million 20-day average | StockAnalysis reported July 31 volume near 4.54 million, well above the 20-day average, so the selloff happened on real sponsorship. |
| Volatility | Elevated | Barchart reported 14-day historical volatility near 54% and a 14-day average true range near $11.88, so position sizing should account for larger swings. |
| Invalidation | Close below $317, then $311 | A close below the 50-day and 100-day cluster weakens the base. A close below $311 would shift focus to the $300 and $281 downside levels. |
SYK AI trading strategy
The SYK AI trading strategy is a rules-based framework, not a personalized recommendation. Use it with live charts, position sizing, earnings dates, Inari and cyber recovery updates, Medicare reimbursement news, and clear invalidation levels.
Look for SYK to hold above the $317 to $321 support cluster, then reclaim the 20-day moving average near $327 and the $334 area on volume above the 20-day average, with improving commentary around Inari backorders and cyber remediation.
A close below $317, or a failed reclaim of the 20-day moving average with rising down-day volume, should invalidate the near-term trend setup.
If SYK pulls back toward $311 to $316 without a new thesis break, compare the selloff with organic sales momentum, Inari recovery timing, backlog delivery, operating margin, cash flow, and reimbursement developments before acting.
Do not treat franchise quality as a substitute for a stop or position limit because premium MedTech multiples can compress quickly after execution misses.
Track organic sales growth, MedSurg and Neurotechnology and Orthopaedics momentum, Inari and Peripheral Vascular backorder relief, cyber remediation spend, adjusted operating margin, free cash flow, M&A and buyback activity, Mako adoption, and Medicare reimbursement rules.
Reduce confidence if growth depends on timing catch-up, if margins fail to recover toward the 150 basis point target, or if guidance relies on multiple expansion rather than durable earnings growth.
Investment research summary
Stryker helps hospitals, surgeons, emergency teams, and healthcare systems improve patient outcomes with implants, instruments, surgical equipment, neurovascular and peripheral vascular tools, emergency care products, and procedure-enabling technology.
The moat is built from surgeon trust, training, switching costs inside operating-room workflows, Mako robotics with more than 2.5 million procedures across 47 countries, regulatory experience, distribution scale, broad product breadth, and long hospital relationships.
The thesis fails if the Inari supply disruption becomes durable share loss, cyber remediation costs exceed plan, procedure growth slows or Medicare reimbursement hits harder, acquisitions dilute returns, or the market stops paying for premium MedTech growth.
Kevin Lobo has compounded Stryker through innovation and acquisitions. The current test is whether management can clear Inari backorders, contain cyber costs, restore margins toward the 150 basis point three-year target, and keep organic growth high single digit.
Stryker sits inside durable healthcare trends: aging populations, orthopedic procedures, hospital workforce productivity, surgical robotics, neurovascular and peripheral vascular treatment, the shift of joint replacement to ambulatory surgery centers, and global access to advanced medical devices.
The current price still assumes premium growth and margin recovery. Margin of safety improves if SYK holds the $317 to $321 support while guidance, Inari recovery, procedure demand, free cash flow, and margin execution remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SYK price | $325.70 close on July 31, 2026, down 6.42% on the Q2 earnings reaction | StockAnalysis.com real-time quote | July 31, 2026 |
| Market capitalization | $124.93 billion, verified as $325.70 x 383.57 million shares with 0.00% deviation | financial_rigor.py market cap verification and StockAnalysis.com | August 2, 2026 |
| Shares outstanding | 383.57 million shares outstanding; 347.57 million float | StockAnalysis.com statistics | August 2, 2026 |
| Q2 2026 reported results | Net sales $6.589 billion up 9.4%, organic sales up 9.0%, reported EPS $3.30 up 44.1%, reported net earnings $1.276 billion up 44.3% | Stryker Q2 2026 earnings release | July 30, 2026 |
| Q2 2026 adjusted results | Adjusted EPS $3.69 up 17.9% versus consensus $3.49, adjusted gross margin 66.0%, adjusted operating margin 27.4% up 170 basis points | Stryker Q2 2026 earnings release and call transcript | July 30, 2026 |
| Q2 2026 segment organic growth | MedSurg and Neurotechnology net sales $3.625 billion with organic growth of 9.2%; Orthopaedics net sales $2.964 billion with organic growth of 8.6% | Stryker Q2 2026 earnings release sales growth analysis | July 30, 2026 |
| 2026 guidance | Organic net sales growth narrowed to 8.3% to 9.3%, adjusted EPS narrowed to $14.95 to $15.10 versus consensus $14.97, with a slightly favorable FX impact expected | Stryker Q2 2026 earnings release and call | July 30, 2026 |
| FY2025 revenue and net earnings | FY2025 net sales $25.116 billion up 11.16%; FY2025 net earnings $3.246 billion up 8.45% | StockAnalysis.com financials and Stryker 2025 Form 10-K | August 2, 2026 |
| TTM cash flow | TTM operating cash flow $5.525 billion, capital expenditures $823 million, free cash flow $4.702 billion; FY2025 free cash flow was $4.283 billion | StockAnalysis.com cash flow statement | August 2, 2026 |
| Cash and marketable securities | $3.476 billion as of June 30, 2026, consisting of $3.391 billion cash and $85 million marketable securities | Stryker Q2 2026 earnings release condensed balance sheet | July 30, 2026 |
| Debt and net cash position | Long-term debt $14.192 billion plus current maturities $750 million for total debt of $14.942 billion as of June 30, 2026; net cash about negative $11.466 billion by financial_rigor.py calc | Stryker Q2 2026 earnings release balance sheet and financial_rigor.py | July 30, 2026 |
| Valuation check | 33.75x trailing EPS, 20.32x forward EPS, 26.57x trailing free cash flow, 4.84x sales, 5.21x book value, 1.08% dividend yield, PEG 1.89 | financial_rigor.py valuation verification and StockAnalysis.com statistics | August 2, 2026 |
| Analyst consensus | Buy rating across 28 analysts with an average target of $383.73, median $382.50, low $315, and high $465 | StockAnalysis.com forecast and analyst ratings | July 31, 2026 |
| Post-earnings analyst target changes | RBC $435 to $420, Raymond James $383 to $370, BTIG $371 to $358, J.P. Morgan $400 to $350, Piper Sandler $420 to $390; UBS upgraded to Buy with a $400 target in late July | StockAnalysis.com forecast latest forecasts via TipRanks | July 31, 2026 |
| Consensus estimates | FY2026 revenue $27.31 billion with adjusted EPS $14.99; FY2027 revenue $29.61 billion with adjusted EPS $16.75 | StockAnalysis.com forecast financial forecast | July 31, 2026 |
| Technical snapshot | 20-day moving average $327.49, 50-day $317.19, 100-day $321.29, 200-day $343.17, 14-day RSI 49.87, 14-day ADX 15.69 | Barchart technical analysis and StockAnalysis.com statistics | July 31, 2026 |
| Short interest | 7.03 million shares short, 1.83% of shares outstanding, 2.55 days to cover | StockAnalysis.com statistics short selling | August 2, 2026 |
| Dividend | Annual dividend of $3.52 per share, 1.08% yield, ex-dividend date June 30, 2026, 16 years of dividend growth | StockAnalysis.com statistics and dividend page | August 2, 2026 |
| Ownership | Insider ownership 9.23%, institutional ownership 80.93% | StockAnalysis.com statistics | August 2, 2026 |
This SYK AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future performance. Forecast ranges are scenarios based on available data as of August 2, 2026 and can be wrong if earnings, cyber recovery, Inari supply, procedure demand, regulation, reimbursement, litigation, acquisitions, or market multiples change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
